Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
44.14 USD | -1.97% | -0.22% | +61.53% |
05-13 | Merus Says US FDA Grants Breakthrough Therapy Designation for Petosemtamab | MT |
05-13 | Merus Carcinoma Treatment Awarded US FDA's Breakthrough Therapy Designation | DJ |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+61.53% | 2.64B | |
+9.15% | 114B | |
+11.55% | 104B | |
-13.44% | 22.41B | |
-1.05% | 22.28B | |
-5.29% | 19.07B | |
-38.29% | 18B | |
-3.72% | 17.89B | |
+7.93% | 14.28B | |
+34.84% | 12.55B |
- Stock Market
- Equities
- MRUS Stock
- News Merus N.V.
- HC Wainwright Adjusts Price Target on Merus to $39 From $45, Maintains Buy Rating